Featured Research

from universities, journals, and other organizations

Young Volunteers Needed For Stanford/Packard Study

Date:
November 24, 2004
Source:
Stanford University Medical Center
Summary:
Itchy red spots on a baby's skin often foretell a worse fate. Asthma later develops in approximately 50 percent of children who have a sibling with eczema or asthma and who, in their early years, have dry-skin rashes known as eczema or atopic dermatitis.

STANFORD, Calif. – Itchy red spots on a baby's skin often foretell a worse fate. Asthma later develops in approximately 50 percent of children who have a sibling with eczema or asthma and who, in their early years, have dry-skin rashes known as eczema or atopic dermatitis.

Researchers at the Stanford University School of Medicine and 27 other institutions across the country are studying whether youngsters who receive prompt, consistent and long-term eczema treatment with a steroid-free cream will be less likely to develop the wheezing that signals the onset of asthma.

"The theory is that inflammation in the skin might make you more sensitive to inflammation in the lungs," said Alfred Lane, MD, professor of dermatology and of pediatrics and director of pediatric dermatology at Lucile Packard Children's Hospital.

There's some scientific evidence to support that idea. Mice primed for allergic skin reactions are also susceptible to an asthmatic lung reaction, Lane noted. But the question remains: if you block the rash, will you also block the wheeze?

In eczema, certain immune cells overreact to harmless substances that come in contact with the skin. Those are the same cells that overreact in the lungs of a person with asthma. "In both asthma and eczema the immune system is too excited, so the goal is to calm it down," Lane said.

Elidel, a steroid-free prescription cream containing pimecrolimus, prevents the excessive immune response that causes eczema, and researchers theorize that perhaps it can do the same for asthma.

To study whether the risk of getting asthma can be reduced in children whose eczema has been pacified at a very young age, the researchers are recruiting children between the ages of 3 months and 18 months who have eczema and whose mothers, fathers or siblings have eczema or asthma.

The volunteers' eczema must have been diagnosed in the previous three months. "We want them right when they first develop it," said Lane. "The idea is the earlier you can improve their skin, the better their outcome will be."

Study participants will be given either Elidel cream or a placebo cream to treat their eczema, and neither they nor their doctors will know which they are using. If the rash remains after a few days of treatment with the cream, all patients may then apply Cutivate, a cream containing a synthetic steroid that also relieves the skin condition.

"This is the standard treatment we would use for children with eczema," Lane said, "but it is a little more aggressive because we follow them more closely. And they get free medications-so they are more likely to use them."

In addition to six years of free medication, the volunteer's parents receive a Palm Pilot on which to record their child's skin condition and treatment.

Usually, Lane said, eczema gets better after 18 months of age, but asthma can develop years later. So the researchers will follow the volunteers for six years to see how many Elidel users start to wheeze compared with those treated only with Cutivate.

Sponsored by Novartis, the maker of Elidel, the study has an additional goal: to gain approval from the Food and Drug Administration to use Elidel in 3- to 18-month-old patients. The cream is already approved for use in patients ages 2 and up and is also routinely prescribed for younger children with eczema despite lacking FDA approval.

As in many clinical trials, Lane said, participants are doing better than patients who aren't part of the study. "The parents are motivated to give their kids better skin care," he explained. "They are applying moisturizers and medications and using the Palm Pilot, so most of the kids are doing really well."

Those interested in the study may call (650) 725-4302 or e-mail the study coordinator at DermStudies@yahoo.com. Information is also available at http://www.atopicmarchstudy.com.


Story Source:

The above story is based on materials provided by Stanford University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Stanford University Medical Center. "Young Volunteers Needed For Stanford/Packard Study." ScienceDaily. ScienceDaily, 24 November 2004. <www.sciencedaily.com/releases/2004/11/041123205215.htm>.
Stanford University Medical Center. (2004, November 24). Young Volunteers Needed For Stanford/Packard Study. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2004/11/041123205215.htm
Stanford University Medical Center. "Young Volunteers Needed For Stanford/Packard Study." ScienceDaily. www.sciencedaily.com/releases/2004/11/041123205215.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins